Referenser och regelverk

    Innehållet är grundat på beprövad erfarenhet, lagar, regelverk, nationella riktlinjer och med stöd från relevanta vetenskapliga studier.

    Referenser

    1. Fass. Skyddsinformation: fakta för förskrivare. Läkemedelsindustriföreningen (LIF);
    2. Arbetsmiljöverket.
    3. Hedmer M, Jönsson BAG and Nygren O. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. Journal of Environmental Monitoring. 2004;6:979.
    4. Hedmer M, Wohlfasrt G. Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. J Environ Monit. 2012;47(7):1968-1975.
    5. Hedmer et al. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. The Annals of Occupational Hygiene. 2005;49(7):629-37.
    6. Wengström Y, Foubert J, Margulies A, Roe H, Bugeia S. Extravasering: Riktlinjer 2007. Extravasation Guidelines 2007.. London: European Oncology Nursing Society (EONS); 2007.
    7. Böhlandt A, Sverdel Y, Schierl R. Antineoplastic drug residues inside homes of chemotherapy patients. Int J Hyg Environ Health. 2017;Jun;220(4):757-765.
    8. Hedmer M, Karlsson JE, Andersson U, Jacobsson H, Nielsen J, Tinnerberg H. Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients. Int Arch Occup Environ Health. 2008;81(3):285-93.
    9. Yuki M, Sekine S, Takase K, Ishida T, Sessink PJ. Exposure of family members to antineoplastic drugs via excreta of treated cancer patients. J Oncol Pharm Pract. 2013;19(3):208-17.
    10. Yuki M, Ishida T, Sekine S. Secondary Exposure of Family Members to Cyclophosphamide After Chemotherapy of Outpatients With Cancer: A Pilot Study. Oncol Nurs Forum. 2015;42(6):665-71.
    11. Connor TH, Shults M, Fraser MP. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37 degrees C using a desiccator technique. Mutat Res. 2000 Oct;10;470(1):85-92.
    12. Opiolka S, Molter W, Goldschmidt R, Erich E, Schoppe G. Umgang mit zytostatika: Besteht aus ausreichender Personenschutz bei der Zytostaika_Zuberitung?. Krankenhaus Technik. 1998;56-8.
    13. Rekommendationer om städning i samband med cytostatikabehandling. Lund: Regionalt cancercentrum Väst; 2018.

    Nedanstående referenser gäller generellt för texterna i ämnet

    Regelverk

    Till toppen av sidan